Publication details
Léčba pacientů infikovaných virem hepatitidy C genotypu 2
| Title in English | Treatment of HCV genotype 2 infection |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | chronic hepatitis C; genotype 2; pegylated interferon; ribavirin; sofosbuvir |
| Description | Introduction: Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. Aims: Retrospectively evaluate the results of therapy of patients with genotype 2 HCV treated during last 15 years at the Department of Infectious Diseases University Hospital Brno and Faculty of Medicine Masaryk University Brno, Czech Republic. Patients and methods: 15 patients (9 men, 6 women, mean age 54.73 +- 13.83 years, median 54 years) with chronic genotype 2 infection were treated at in our department during last 15 years. It is the biggest group of patients with this diagnosis treated in the Czech Republic. Proportion of genotype 2 subtypes was following: 1 times subtype 2a, 2 times subtype 2a/2c, 5 times subtype 2b, in the rest 7 cases only genotype 2 was determined without possibility to determinate subtype. Results: 9 patients were treated with the combination of peginterferon a-2a (180 ug once weekly subcutaneously) and ribavirin (1 000 or 1 200 mg daily according to the weight) for 24 weeks in the years 2002-2015, sustained virological response (SVR) achieved 6 of them (67 %).Two relapses and one breakthrough were recorded. 7 patients were treated with combination of sofosbuvir (400 mg daily) and ribavirin (1 000 or 1 200 mg daily according to the weight) for 12 weeks in the years 2015-2016 - 6 of them were treatment naTve, one after breakthrough in previous therapy. All of these 7 patients achieved SVR (100 %). Conclusions: Genotype 2 therapy still not represents serious therapeutic problem. The number of difficultly treatable patientrfrgratJuaHy increasing in many well-developed countries during last several years. However the therapeutic possibilities are quickly developing. |